SoureBio Executive Chairman, Jay LeCoque, discusses the key drivers to their five fold EBITDA growth

Jay covers the recent COVID testing agreements with the NHS and a major high street pharmacy as well as their partnership agreement with Oxford Nanopore. In addition Jay touches on future acquisition plans and the possibility of offering mobile testing.

You might like

© 2022 The Latest StockMarket News and Interviews